Skip to content

Is combined laser treatment effective for patients with periodontal disease?

Combined application of Er:YAG and low level diode lasers in treatment of periodontitis: A split-mouth, randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN11340841
Enrollment
24
Registered
2021-11-24
Start date
2021-12-01
Completion date
Unknown
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate or severe periodontitis Oral Health

Interventions

The study will use a split-mouth design, with each patient serving as their own control. Each quadrant (right upper jaw, left upper jaw, left lower jaw, right lower jaw) will be randomly allocated int

Sponsors

Beijing Chao-Yang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 35-70 years 2. Minimum of 20 teeth (4 per quadrant) 3. It is clinically diagnosed as extensive stage III-IV periodontal disease: the heaviest site of interproximal attachment loss is =5 mm, radiologic bone loss extends to 1/3 of the root and above, PD = 6mm, vertical bone absorption =3 mm, cumulative bone resorption >30% 4. Good general health

Exclusion criteria

Exclusion criteria: 1. Received periodontal treatment within the previous 6 months 2. Received systemic antibiotic therapy within the previous 6 months 3. Suffered systemic diseases that could influence therapy outcome (e.g. diabetes mellitus, blood disease) 4. Pregnant

Design outcomes

Primary

MeasureTime frame
1. Probing depth (PD) measured using periodontal probing at baseline, 3 months, and 6 months 2. Clinical attachment level (CAL) measured using periodontal probing at baseline, 3 months, and 6 months

Secondary

MeasureTime frame
1. Bleeding index (BI) measured using periodontal probing at baseline, 3 months, and 6 months 2. Plaque index (PLI) assessed by an examiner using a scale of 0 to 3 (where 0= No plaque, 1= Cannot see plaque but plaque can be detected with probe, 2= Moderate plaque can be seen, and 3= Lots of plaque can be seen) at baseline, 3 months, and 6 months

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026